Keiji Dohi

Title: Keiji Dohi: Innovator in Monoclonal Antibodies

Introduction

Keiji Dohi, based in Osaka, Japan, is an accomplished inventor with three registered patents to his name. His contributions primarily focus on advancements in the field of immunoassays, particularly involving monoclonal antibodies that have implications for medical diagnostics. Dohi's innovative work demonstrates a commitment to improving healthcare through scientific discovery.

Latest Patents

One of Dohi's latest patents is centered around the development of monoclonal antibodies for N-peptide, specifically designed to facilitate a sandwich immunoassay. This method allows for the rapid and straightforward measurement of N-peptide by utilizing two distinct monoclonal antibodies that recognize different portions of the peptide. The process involves incubating a sample with a first monoclonal antibody, followed by the addition of a labeled second monoclonal antibody, resulting in the detection of an antigen-antibody complex within the mixture.

Another significant patent is related to the hybridoma technology used to produce monoclonal antibodies targeting N-peptide. This innovation mirrors the sandwich immunoassay concept, outlining a method that includes incubating a sample with the first and second monoclonal antibodies and subsequently detecting the formed complex. These patented technologies showcase Dohi's focus on delivering reliable and efficient diagnostic tools.

Career Highlights

Keiji Dohi is currently affiliated with Shionogi & Company Limited, where he engages in pioneering research and development efforts. His role at the company allows him to harness his expertise in biotechnology and contribute significantly to the field of medical diagnostics. Dohi's patents reflect his commitment to advancing scientific knowledge and improving patient outcomes through innovative solutions.

Collaborations

Throughout his career, Dohi has collaborated with esteemed colleagues such as Yoshito Numata and Hidehisa Asada. These partnerships enhance his research endeavors and facilitate the sharing of ideas that lead to groundbreaking inventions in the domain of monoclonal antibodies and immunoassays.

Conclusion

Keiji Dohi has established himself as a prominent inventor in the biotechnology sector, particularly concerning monoclonal antibodies and their applications in medical diagnostics. His innovative patents and collaborative efforts highlight his role in enhancing healthcare solutions, positioning him as a key figure in the scientific community. As research continues to develop in this field, Dohi's contributions will likely play a crucial role in shaping future innovations.